Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Non Operating Income (2021 - 2025)

Verrica Pharmaceuticals has reported Non Operating Income over the past 5 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Non Operating Income at $4.8 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 143.33% YoY), and the annual figure for FY2025 was -$3000.0, up 82.35%.
  • Non Operating Income for Q4 2025 was $4.8 million at Verrica Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Over the last five years, Non Operating Income for VRCA hit a ceiling of $4.8 million in Q4 2025 and a floor of -$4.2 million in Q4 2021.
  • Median Non Operating Income over the past 5 years was -$1.1 million (2021), compared with a mean of -$1.0 million.
  • Biggest five-year swings in Non Operating Income: soared 99.9% in 2022 and later crashed 190000.0% in 2025.
  • Verrica Pharmaceuticals' Non Operating Income stood at -$4.2 million in 2021, then rose by 24.74% to -$3.1 million in 2022, then soared by 91.85% to -$256000.0 in 2023, then soared by 99.61% to -$1000.0 in 2024, then soared by 481700.0% to $4.8 million in 2025.
  • The last three reported values for Non Operating Income were $4.8 million (Q4 2025), -$1.9 million (Q3 2025), and -$1.3 million (Q2 2025) per Business Quant data.